Login / Signup

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer.

Xiuwen GuanZongbi YiQiao LiShanshan ChenYing FanJiayu WangYang LuoPin ZhangQing LiBinghe Xu
Published in: Signal transduction and targeted therapy (2023)
Keyphrases
  • metastatic breast cancer
  • free survival
  • randomized controlled trial
  • squamous cell carcinoma
  • clinical trial
  • double blind
  • placebo controlled